Product
GSK6097608
4 clinical trials
4 indications
Indication
CancerIndication
Head and NeckIndication
lung cancerIndication
Non-Small CellClinical trial
A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and NeckStatus: Recruiting, Estimated PCD: 2025-09-17
Clinical trial
A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants With Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-01-17
Clinical trial
A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-09-03
Clinical trial
A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC ParticipantsStatus: Recruiting, Estimated PCD: 2025-07-08